Kevin Macdonald, MD
Family Medicine · New Bern, NCNPI 1962939280
Payments from drug & device makers
Across 183 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$477
- GSK$420
- Amgen$362
- Novo Nordisk$285
- Pfizer$205
- AbbVie$203
- plus $825 from 20 others
What the payments were for
- Food & beverage$2,776100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 28 | $477 |
| GSK | 29 | $420 |
| Amgen | 27 | $362 |
| Novo Nordisk | 19 | $285 |
| Pfizer | 17 | $205 |
| AbbVie | 11 | $203 |
| Abbott | 11 | $163 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $105 |
| Astellas Pharma US Inc | 4 | $71 |
| Boehringer Ingelheim | 4 | $59 |
| AstraZeneca | 3 | $52 |
| Dexcom, Inc. | 3 | $51 |
| Currax Pharmaceuticals LLC | 3 | $44 |
| Medtronic | 2 | $39 |
| Bayer | 2 | $32 |
| Vertex | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| C2n Diagnostics, LLC | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Novartis | 1 | $15 |
| Merck | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$2,776 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 161 | $204,425 |
| EliquisApixaban | 244 | $186,972 |
| MounjaroTirzepatide | 55 | $73,612 |
| JardianceEmpagliflozin | 62 | $71,785 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $52,499 |
| TrulicityDulaglutide | 42 | $45,442 |
| FarxigaDapagliflozin Propanediol | 18 | $24,105 |
| MyrbetriqMirabegron | 33 | $23,990 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 43 | $16,527 |
| Victoza 3-PakLiraglutide | 18 | $15,988 |
| VraylarCariprazine Hcl | 12 | $15,717 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 70 | $15,437 |
| TradjentaLinagliptin | 15 | $12,912 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $12,174 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $9,805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $285 | $204,425161 claims |
| PfizerEliquis | $205 | $186,972244 claims |
| Lilly USA, LLCMounjaro, Trulicity | $477 | $119,05597 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $59 | $90,73088 claims |
| GSKTrelegy Ellipta, Shingrix, Anoro Ellipta | $420 | $80,111155 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort, Pulmicort Flexhaler | $52 | $37,55652 claims |
| Astellas Pharma US IncMyrbetriq | $71 | $23,99033 claims |
| AbbVieVraylar, Synthroid | $203 | $20,31793 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in New Bern
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.